113 related articles for article (PubMed ID: 8396823)
21. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
Müller D; Frey K; Kontermann RE
J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
[TBL] [Abstract][Full Text] [Related]
22. Development of humanized antibodies as cancer therapeutics.
Qu Z; Griffiths GL; Wegener WA; Chang CH; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
Methods; 2005 May; 36(1):84-95. PubMed ID: 15848077
[TBL] [Abstract][Full Text] [Related]
23. Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer.
Zhang X; Feng J; Ye X; Yao Y; Zhou P; Chen X
Gynecol Oncol; 2006 Dec; 103(3):848-52. PubMed ID: 16806435
[TBL] [Abstract][Full Text] [Related]
24. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Brischwein K; Schlereth B; Guller B; Steiger C; Wolf A; Lutterbuese R; Offner S; Locher M; Urbig T; Raum T; Kleindienst P; Wimberger P; Kimmig R; Fichtner I; Kufer P; Hofmeister R; da Silva AJ; Baeuerle PA
Mol Immunol; 2006 Mar; 43(8):1129-43. PubMed ID: 16139892
[TBL] [Abstract][Full Text] [Related]
25. 14G2a anti-GD2 crossreactivity with the CD166 antigen.
Agrawal V; Frankel AE
J Immunother; 2010; 33(9):1014-5. PubMed ID: 20948433
[No Abstract] [Full Text] [Related]
26. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
[TBL] [Abstract][Full Text] [Related]
27. Dual-specific T cells combine proliferation and antitumor activity.
Kershaw MH; Westwood JA; Hwu P
Nat Biotechnol; 2002 Dec; 20(12):1221-7. PubMed ID: 12415288
[TBL] [Abstract][Full Text] [Related]
28. Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.
Wels W; Groner B; Hynes NE
Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():113-28. PubMed ID: 8815001
[No Abstract] [Full Text] [Related]
29. Current perspectives of bispecific antibody-based immunotherapy.
Talac R; Nelson H
J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049
[TBL] [Abstract][Full Text] [Related]
30. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
31. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Strome SE; Dong H; Tamura H; Voss SG; Flies DB; Tamada K; Salomao D; Cheville J; Hirano F; Lin W; Kasperbauer JL; Ballman KV; Chen L
Cancer Res; 2003 Oct; 63(19):6501-5. PubMed ID: 14559843
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibodies in clinical hematology and oncology.
Nagorsen D; Thiel E
Curr Opin Investig Drugs; 2007 Dec; 8(12):996-1001. PubMed ID: 18058570
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic antibodies: magic bullets hit the target.
Gura T
Nature; 2002 Jun; 417(6889):584-6. PubMed ID: 12050630
[No Abstract] [Full Text] [Related]
34. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
[TBL] [Abstract][Full Text] [Related]
35. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
36. [Development of cancer immunotherapy by next generation multi-targeting CAR-T cells].
Sakoda Y; Tamada K
Rinsho Ketsueki; 2014 Jun; 55(6):651-6. PubMed ID: 24975334
[No Abstract] [Full Text] [Related]
37. Transferrin receptors: structure and function.
Testa U
Curr Top Hematol; 1985; 5():127-61. PubMed ID: 2982550
[No Abstract] [Full Text] [Related]
38. Applications of monoclonal antibodies in cancer therapy.
Dillman RO; Royston I
Br Med Bull; 1984 Jul; 40(3):240-6. PubMed ID: 6087968
[No Abstract] [Full Text] [Related]
39. [Bispecific antibodies in hematology and oncology].
Repp R; Valerius T; Bargou R
Internist (Berl); 2001 Jun; 42(6):854-9. PubMed ID: 11449632
[No Abstract] [Full Text] [Related]
40. [Receptors for biologically active substances in the light of the studies using monoclonal antibodies].
Lipski S
Postepy Hig Med Dosw; 1989; 43(2-4):161-97. PubMed ID: 2562034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
